Eurobio Oncology

EndoPredict^®: Chemotherapy Benefit Prediction

Confident Chemotherapy Decisions in Breast Cancer with EndoPredict^®

Making the right treatment decisions in early-stage breast cancer is critical. EndoPredict is the only second-generation gene expression test that provides a personalized up to 15-year prognosis and predicts the individual 10-year benefit of chemotherapy for premenopausal and postmenopausal women with ER+/HER2-, node-negative or node-positive breast cancer.^1-3

Almost all women with ER+/HER2– breast cancer receive at least five years of endocrine therapy. However, identifying who will benefit from additional chemotherapy remains a challenge.

EndoPredict helps clinicians and patients make informed decisions about chemotherapy, improving quality of life by avoiding unnecessary treatment while ensuring that those who will benefit receive the right therapy.

EndoPredict^® Guides Chemotherapy Decisions by Assessing Treatment Benefit¹

The Only Test Accurately Predicting Individual 10-Year Chemotherapy Benefit¹

10-year risks by EPclin Risk Score for endocrine treatment vs. endocrine treatment plus chemotherapy¹

High EPclin Risk Score: Women in this group who received endocrine therapy + chemotherapy had a significantly lower 10-year recurrence risk compared to those who received endocrine therapy alone. This indicates that patients with a high-risk score benefit from adjuvant chemotherapy.
Low EPclin Risk Score: There was no statistically significant difference in recurrence risk between women treated with endocrine therapy + chemotherapy and endocrine therapy alone. This suggests that chemotherapy is unlikely to provide additional benefit for these patients.
Statistical Significance: The test for interaction confirms that EPclin effectively differentiates between those who will benefit from chemotherapy and those who will not.

The EPclin Risk Score provides a continuous and precise assessment of chemotherapy benefit, ensuring informed treatment decisions. At the guideline-recommended 10% recurrence risk cut-off, chemotherapy benefit is approximately 3% – a rate comparable to the risk of serious chemotherapy side effects.

Chemotherapy Benefit Prediction Prospectively Confirmed^4,5

Chemotherapy benefit validation in over 3,700 patients was confirmed in two real-world prospective analyses, including 550 patients with over five years of follow-up. EndoPredict is the only test that accurately predicts 10-year chemotherapy benefit for each individual patient, enabling truly personalized treatment planning.

CTx Benefit Validation¹

10-year distant recurrence risk in high-risk patients (EPclin score 5)

With chemotherapy

26 %

Without chemotherapy

46 %

Prospettive Real World CTx Benefit data⁴

5-year distant recurrence risk in high-risk patients (EPclin score >3.33)

With chemotherapy

11 %

Without chemotherapy

31 %

This evidence underscores the value of EndoPredict in guiding personalized treatment, helping clinicians and patients avoid unnecessary chemotherapy while ensuring high-risk patients receive the treatment they need.

Beyond Chemotherapy Benefit Prediction

EndoPredict goes further than chemotherapy benefit prediction by providing robust prognostic information on distant recurrence risk at both 10 yearst⁶ and across an extended 5–15 year timeframet². This long-term perspective supports evidence-based decisions on extended endocrine therapy and long-term patient management, ensuring optimal treatment planning across the entire disease course.

EndoPredict^® Testing – Fast, Local, Reliable

The EndoPredict prognostic and predictive breast cancer test is performed in certified local laboratories, delivering reliable results within just a few days.

Physicians can conveniently order EndoPredict through a wide network of participating labs.

Use the link below to find a local lab and place your order. Have questions? Contact us anytime – we’re here to help.

References

Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019
Filipits M. et al.: Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019
Constantinidou A. et al.: Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer. Clin. Cancer Res. 2022
Klein, E. et al.: Long-term outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor positive, HER2-negative early breast cancer. Breast Cancer Res Treat. 2024
Schmitt, W. D. et al.: Retrospective evaluation of outcomes in a real-world, prospective cohort using EndoPredict: Results from the Charité registry. SABCS 2022
Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin. Cancer Res. 2011